Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia

Treatment of chronic lymphocytic leukemia (CLL) patients with standard dose infusion of rituximab (RTX), 375 mg/m2, induces clearance of malignant cells from peripheral blood after infusion of 30 mg of RTX. After completion of the full RTX infusion, substantial recrudescence of CLL cells occurs, and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Immunology 2006-11, Vol.177 (10), p.7435-7443
Hauptverfasser:	Williams, Michael E, Densmore, John J, Pawluczkowycz, Andrew W, Beum, Paul V, Kennedy, Adam D, Lindorfer, Margaret A, Hamil, Susan H, Eggleton, Jane C, Taylor, Ronald P
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Murine-Derived Antigens, CD20 - blood Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Complement C3 - metabolism Dose-Response Relationship, Immunologic Drug Administration Schedule Drug Delivery Systems Female Humans Infusions, Intravenous Leukemia, Lymphocytic, Chronic, B-Cell - blood Leukemia, Lymphocytic, Chronic, B-Cell - immunology Leukemia, Lymphocytic, Chronic, B-Cell - therapy Lymphocyte Count Lymphocyte Depletion Male Middle Aged Rituximab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!